Latest Conference Articles

CARTITUDE-4 data show heterogeneous outcomes with cilta-cel after progression on bridging therapy in relapsed/refractory multiple myeloma.

Real-world data show over an 40% response rate for lifileucel TIL therapy, for previously treated advanced melanoma.

Only a proportion of patients with advanced melanoma proceeded to TIL therapy following referral in a real-world setting.

Cilta-cel was linked with low progression events and a potential cure fraction in relapsed/refractory multiple myeloma.

Adoptive cell therapy elicited MRD-negative responses with low rates of GVHD and neurotoxicities in adult patients with high-risk B-ALL.

A real-world cilta-cel study revealed a link between high lymphocyte peaks and failed bridging to parkinsonism and nonrelapse mortality, potentially guiding early intervention.

Orca-T/reduced-intensity conditioning was effective and decreased GVHD incidence vs PTCy/reduced-intensity conditioning in hematologic malignancies.

Real-world data confirm the importance of tumor debulking with bridging therapy to reduce the risk of parkinsonism and NRM with cilta-cel in myeloma.

Ustekinumab plus prophylaxis did not reduce acute GVHD in patients who underwent HCT from matched unrelated donors.

No serious adverse effects were observed with TRX103 in patients with hematologic malignancies undergoing HLA-mismatched HCT.

Prophylactic dexamethasone did not reduce the risk of developing DNT, nor the severity of DNT presentation, in cilta cel–treated myeloma with high ALC.

Acalabrutinib yielded durable organ-specific responses and a manageable safety profile in patients with steroid-refractory chronic graft-vs-host disease.

Ahead of the 2026 Transplantation & Cellular Therapy Meetings, experts preview data on CAR T-cell therapy efficacy, donor access, and toxicity mitigation.

Experts reflect on pivotal data from the 2026 Gastrointestinal Cancers Symposium that are set to change practice in HCC, CRC, and other GI cancers.

The addition of mFOLFOX6 and bevacizumab to atezolizumab improved PFS compared with atezolizumab monotherapy in dMMR/MSI-H mCRC.

Encorafenib plus cetuximab and FOLFIRI significantly improved response vs standard therapy in first-line BRAF V600E–mutant metastatic colorectal cancer.

Penipulimab plus anlotinib and chemotherapy showed improved efficacy compared with chemotherapy alone in treatment-naïve metastatic pancreatic cancer.

Nivolumab plus ipilimumab continued to yield an efficacy and safety benefit vs lenvatinib or sorafenib in previously untreated, unresectable HCC.

Atezolizumab plus bevacizumab could yield superior outcomes compared with TACE in intermediate-stage HCC.

Results from ReFocus showed a manageable safety profile and positive antitumor activity for lirafugratinib in FGFR2-mutated cholangiocarcinoma.

Neoadjuvant tislelizumab plus chemoradiotherapy yielded improved response rates in gastric cancer and gastroesophageal junction adenocarcinoma.

Adjuvant pembrolizumab did not improve RFS vs placebo in HCC following complete radiological response after surgical resection or local ablation.

CAR-like T-cells, PD-1 inhibitor, and SOX was active in previously untreated metastatic gastric or GEJ adenocarcinoma.

ECOG performance status captured only part of the patient experience in advanced gastric or gastroesophageal junction adenocarcinoma.

Total neoadjuvant chemotherapy plus chemoradiotherapy was identified as a preferred candidate for future study in resectable gastric adenocarcinoma.

Zolbetuximab plus mFOLFOX6 and nivolumab was effective and tolerable across biomarker-defined subgroups in unresectable gastric/GEJ adenocarcinoma.

HERIZON-GEA-01 is the first phase 3 study to demonstrate a median PFS greater than 1 year, and a median OS greater than 2 years in metastatic GEA.

NXC-201 demonstrated organ responses in 70% of evaluable patients with relapsed/refractory light chain amyloidosis.

Real-world elranatamab led to higher response rates despite less favorable baseline characteristics vs real-world teclistamab in R/R multiple myeloma.

A mobile health intervention was associated with improvements to general and cancer-specific quality of life in AYA breast cancer survivors.